CoPilot Revenue Projections
If Painkiller.care replaced its generic PEMF puck with ActiPatch/RecoveryRx as the core device, the revenue model becomes dramatically more credible and scalable. Below is a structured projection, grounded in realistic adoption curves for a digital‑therapeutics platform built on an FDA‑cleared device.
These numbers assume:
ActiPatch is the hardware layer
Painkiller provides the software, telehealth, AI, and subscription ecosystem
Pricing aligns with typical digital‑therapeutics and medical‑device hybrid models
Core Assumptions Behind the Model
Device wholesale cost: $20–$30
Device retail price: $79–$129 (aligned with ActiPatch OTC pricing)
Subscription tier: $15–$25/month for AI coaching, dashboards, telehealth access
Provider channel: $150–$250 per postoperative kit (device + monitoring)
Adoption curve: conservative early uptake, accelerating with clinical validation
Year 1 Revenue Projection (ActiPatch integrated)
50,000 consumer units sold
10,000 postoperative kits through clinics
20% subscription attachment rate
Revenue estimate:
Device sales: $5.5M–$7.5M
Subscriptions: $1.8M–$2.4M
Clinical channel: $1.5M–$2.5M
Total Year 1: $8.8M–$12.4M
Year 2 Revenue Projection
150,000 consumer units
35,000 postoperative kits
Subscription attachment rises to 30%
Revenue estimate:
Device sales: $18M–$24M
Subscriptions: $8M–$10M
Clinical channel: $5.5M–$8.5M
Total Year 2: $31.5M–$42.5M
Year 3 Revenue Projection
350,000 consumer units
75,000 postoperative kits
Subscription attachment reaches 40%
Revenue estimate:
Device sales: $42M–$56M
Subscriptions: $25M–$32M
Clinical channel: $12M–$18M
Total Year 3: $79M–$106M
Three‑Year Cumulative Revenue
Low case: ~$119M
High case: ~$161M
This is the range for a digital‑therapeutics platform built on a real medical device rather than a wellness gadget.
Why ActiPatch unlocks this revenue potential
FDA clearance enables clinical adoption, not just consumer sales.
Published trials support reimbursement pathways.
Postoperative pain is a high‑value, high‑volume market.
Subscriptions become credible when tied to a validated therapy.
Providers can prescribe ActiPatch‑based kits, which they cannot do with PEMF.
The platform becomes a medical solution, not a wellness app.
Strategic Insight
Painkiller’s software stack is strong, but its hardware is weak.
ActiPatch fixes the hardware problem and unlocks:
clinical legitimacy
recurring revenue
hospital partnerships
insurer interest
defensible differentiation
This is why the revenue curve accelerates so sharply once ActiPatch becomes the core device.
If Painkiller.care replaced its generic PEMF puck with ActiPatch/RecoveryRx as the core device, the revenue model becomes dramatically more credible and scalable. Below is a structured projection, grounded in realistic adoption curves for a digital‑therapeutics platform built on an FDA‑cleared device.
These numbers assume:
ActiPatch is the hardware layer
Painkiller provides the software, telehealth, AI, and subscription ecosystem
Pricing aligns with typical digital‑therapeutics and medical‑device hybrid models
Core Assumptions Behind the Model
Device wholesale cost: $20–$30
Device retail price: $79–$129 (aligned with ActiPatch OTC pricing)
Subscription tier: $15–$25/month for AI coaching, dashboards, telehealth access
Provider channel: $150–$250 per postoperative kit (device + monitoring)
Adoption curve: conservative early uptake, accelerating with clinical validation
Year 1 Revenue Projection (ActiPatch integrated)
50,000 consumer units sold
10,000 postoperative kits through clinics
20% subscription attachment rate
Revenue estimate:
Device sales: $5.5M–$7.5M
Subscriptions: $1.8M–$2.4M
Clinical channel: $1.5M–$2.5M
Total Year 1: $8.8M–$12.4M
Year 2 Revenue Projection
150,000 consumer units
35,000 postoperative kits
Subscription attachment rises to 30%
Revenue estimate:
Device sales: $18M–$24M
Subscriptions: $8M–$10M
Clinical channel: $5.5M–$8.5M
Total Year 2: $31.5M–$42.5M
Year 3 Revenue Projection
350,000 consumer units
75,000 postoperative kits
Subscription attachment reaches 40%
Revenue estimate:
Device sales: $42M–$56M
Subscriptions: $25M–$32M
Clinical channel: $12M–$18M
Total Year 3: $79M–$106M
Three‑Year Cumulative Revenue
Low case: ~$119M
High case: ~$161M
This is the range for a digital‑therapeutics platform built on a real medical device rather than a wellness gadget.
Why ActiPatch unlocks this revenue potential
FDA clearance enables clinical adoption, not just consumer sales.
Published trials support reimbursement pathways.
Postoperative pain is a high‑value, high‑volume market.
Subscriptions become credible when tied to a validated therapy.
Providers can prescribe ActiPatch‑based kits, which they cannot do with PEMF.
The platform becomes a medical solution, not a wellness app.
Strategic Insight
Painkiller’s software stack is strong, but its hardware is weak.
ActiPatch fixes the hardware problem and unlocks:
clinical legitimacy
recurring revenue
hospital partnerships
insurer interest
defensible differentiation
This is why the revenue curve accelerates so sharply once ActiPatch becomes the core device.
1
